<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000200121</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000200011</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Respuesta farmacogenética a escitalopram en pacientes geriátricos en Guatemala]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacogenetic response to escitalopram in geriatric patients in Guatemala]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Xajil Ramos]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaitán Izaguirre]]></surname>
<given-names><![CDATA[GME]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna Aguilera]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas Rosales]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Higueros Villagrán]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saldaña Santiago]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de San Carlos de Guatemala Facultad de Ciencias Químicas y Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Roosevelt Departamento de Medicina Interna Clínica del Adulto Mayor]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Biofarn  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Biofarn  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Red Latinoamericana de Implementación y Validación de Guías Clínicas Farmacogenómicas (RELIVAF)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>121</fpage>
<lpage>125</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000200121&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000200121&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000200121&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivos:  El escitalopram es un fármaco antidepresivo del grupo de los inhibidores selectivos de la recaptación de serotonina utilizado ampliamente en el tratamiento del síndrome depresivo mayor. Este medicamento es metabolizado por la enzima CYP2C19 del complejo enzimático citocromo P450, y se conoce que variaciones genéticas en esta enzima están directamente relacionadas a variaciones en la respuesta farmacológica al escitalopram, en eficacia y toxicidad. El objetivo de este estudio fue determinar la presencia de variantes alélicas para CYP2C19 en pacientes geriátricos tratados con escitalopram y evaluar el ajuste al tratamiento farmacológico con escitalopram de acuerdo con su perfil farmacogenético.  Materiales y métodos:  Se realizó un estudio cuantitativo, descriptivo y transversal. La muestra se conformó por 36 pacientes geriátricos de ambos sexos, diagnosticados con síndrome depresivo mayor y tratados con escitalopram en la Clínica del Adulto Mayor del Hospital Roosevelt durante marzo a agosto de 2017. Para la determinación de la presencia de variantes alélicas se utilizó la técnica de análisis de reacción en cadena de la polimerasa-polimorfismos de longitud de fragmentos de restricción (PCR-RFLP).  Resultados:  Se encontró presencia de variantes alélicas en 4 pacientes (11,1%). Según los diplotipos encontrados, 32 pacientes (88,9%) correspondieron al fenotipo metabolizador extensivo y 4 (11,1%) al intermedio, no se encontraron casos de fenotipos metabolizadores pobres.  Conclusiones:  En todos los casos se realizó intervención farmacéutica con recomendación terapéutica al médico. En ningún caso fue necesario reajuste de dosis. La frecuencia de la presencia de variantes alélicas encontrada para Guatemala fue similar al promedio de frecuencia multiétnica conocida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objectives:  Escitalopram is an antidepressant drug from the group of selective serotonin reuptake inhibitors widely used in the treatment of major depressive syndrome. This drug is metabolized by the enzyme CYP2C19 of the cytochrome P450 enzyme complex and it is known that genetic variations in this enzyme are directly related to variations in the pharmacological response to escitalopram, in efficacy and toxicity. The aim of this study was to determine the presence of allelic variants for CYP2C19 in geriatric patients treated with escitalopram and to evaluate the adjustment to pharmacological treatment with escitalopram according to their pharmacogenetic profile.  Materials and methods:  A quantitative, descriptive and cross-sectional study was conducted. The sample consisted of 36 geriatric patients of both sexes, diagnosed with major depressive syndrome and treated with escitalopram in the Senior Adult Clinic of the Roosevelt Hospital of Guatemala during March to August 2017. For the determination of the presence of allelic variants the analysis technique of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used.  Results:  Allelic variants were found in 4 patients (11.1%). 32 patients (88.9%) corresponded to the extensive metabolizer phenotype and 4 (11.1%) to the intermediate, no cases of poor metabolizing phenotypes were found.  Conclusions:  In all cases, a pharmaceutical intervention was carried out with therapeutic recommendation to the doctor. In no case was dose readjustment necessary. The frequency of the presence of allelic variants found for Guatemala was similar to the known multiethnic frequency average.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Farmacogenética]]></kwd>
<kwd lng="es"><![CDATA[escitalopram]]></kwd>
<kwd lng="es"><![CDATA[pacientes geriátricos]]></kwd>
<kwd lng="es"><![CDATA[CYP2C19]]></kwd>
<kwd lng="es"><![CDATA[recomendación terapéutica]]></kwd>
<kwd lng="en"><![CDATA[Pharmacogenetics]]></kwd>
<kwd lng="en"><![CDATA[escitalopram]]></kwd>
<kwd lng="en"><![CDATA[geriatric patients]]></kwd>
<kwd lng="en"><![CDATA[CYP2C19]]></kwd>
<kwd lng="en"><![CDATA[therapeutic recommendation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baye]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilke]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mapping genes that predict treatment outcome in admixed populations]]></article-title>
<source><![CDATA[The Pharmacogenomics Journal]]></source>
<year>2010</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>465-77</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomalik Scharte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lazar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuhr]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchheiner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical role of genetic polymorphisms in drug-metabolizing enzymes]]></article-title>
<source><![CDATA[The Pharmacogenomics Journal]]></source>
<year>2008</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-15</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barak]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Swartz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baruch]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis]]></article-title>
<source><![CDATA[Progress in Neuro-Psychopharmacology and Biological Psychiatry]]></source>
<year>2011</year>
<volume>35</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1744-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Higueros]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Saldaña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Xajil]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promiscuity of NSAIDs, the secret of their effectiveness: perspective]]></article-title>
<source><![CDATA[Pharmacology Online]]></source>
<year>2017</year>
<volume>1</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huezo Diaz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Perroud]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Virding]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP]]></article-title>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2012</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>398-407</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altar]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Hornberger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shewade]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garrison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mrazek]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy]]></article-title>
<source><![CDATA[International Review of Psychiatry]]></source>
<year>2013</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>509-33</page-range><publisher-loc><![CDATA[England ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodgson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tansey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dernovsek]]></surname>
<given-names><![CDATA[MZ]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Henigsberg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maier]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic differences in cytochrome P450 enzymes and antidepressant treatment response]]></article-title>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2014</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-41</page-range><publisher-loc><![CDATA[England ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hicks]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Sangkuhl]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Leckband]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors]]></article-title>
<source><![CDATA[Clinical Pharmacology &amp; Therapeutics]]></source>
<year>2015</year>
<volume>98</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>127-34</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Herazo]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depresión en ancianos]]></article-title>
<source><![CDATA[Revista de la Facultad de Medicina]]></source>
<year>2009</year>
<volume>57</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-55</page-range><publisher-name><![CDATA[Universidad Nacional de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Funk]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Bostwick]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Comparison of the Risk of QT Prolongation Among SSRIs]]></article-title>
<source><![CDATA[Annals of Pharmacotherapy]]></source>
<year>2013</year>
<volume>47</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1330-41</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ueta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mizuno]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel mutations in the cytochrome P450 2C19 gene: A pitfall of the PCR-RFLP method for identifying a common mutation]]></article-title>
<source><![CDATA[Journal of Human Genetics]]></source>
<year>2006</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>118-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jureidini]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Chamseddine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Keleshian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naoufal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zahed]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hakime]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of CYP2C19 polymorphisms in the Lebanese population]]></article-title>
<source><![CDATA[Molecular Biology Reports]]></source>
<year>2011</year>
<volume>38</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>5449-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosemary]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Adithan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance]]></article-title>
<source><![CDATA[Current Clinical Pharmacology]]></source>
<year>2007</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93-109</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kudzi]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dodoo]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population]]></article-title>
<source><![CDATA[BMC Medical Genetics]]></source>
<year>2009</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo Villalta]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bayá]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Horiuchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study]]></article-title>
<source><![CDATA[European Journal of Clinical Pharmacology]]></source>
<year>2005</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>179-84</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaneko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bergqvist]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Taleo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayakawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ishizaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorkman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations]]></article-title>
<source><![CDATA[Pharmacogenetics]]></source>
<year>1999</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>317-26</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whirl Carrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Hebert]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sangkuhl]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thorn]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacogenomics knowledge for personalized medicine]]></article-title>
<source><![CDATA[Clinical Pharmacology and Therapeutics]]></source>
<year>2012</year>
<volume>92</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>414-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hampton]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Daubresse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Budnitz]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emergency Department Visits by Adults for Psychiatric Medication Adverse Events]]></article-title>
<source><![CDATA[JAMA Psychiatry]]></source>
<year>2014</year>
<volume>71</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1006-14</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jukiá]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Opel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ström]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo Roa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miksys]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Novalen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment]]></article-title>
<source><![CDATA[Molecular Psychiatry]]></source>
<year>2017</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1155-63</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santizo]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Müllers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia]]></article-title>
<source><![CDATA[Medical Oncology]]></source>
<year>2013</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tutton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacogenomic biomarkers in drug labels: what do they tell us?]]></article-title>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2014</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>297-304</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Weitzel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacogenetics: Using Genetic Information to Guide Drug Therapy]]></article-title>
<source><![CDATA[American Family Physician]]></source>
<year>2015</year>
<volume>92</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>588-94</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crews]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and Implementation of a Pharmacist-Managed.]]></article-title>
<source><![CDATA[American Journal of Health-System Pharmacy]]></source>
<year>2011</year>
<volume>68</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>143-50</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Céspedes Garro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fariñas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Barrantes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacogenetics in Central American healthy volunteers: Interethnic variability]]></article-title>
<source><![CDATA[Drug Metabolism and Personalized Therapy]]></source>
<year>2015</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
